The company provides complete manufacturing services from process development and clinical manufacturing through commercial launch at its new 150,000 ft2 facility, with a customer base that has transitioned from primarily substantial government contracts to now focus almost 100% on commercial activity servicing the biotech marketplace. Paragon's contract development and manufacturing organization focuses on production and purification of monoclonal antibodies, recombinant proteins, viral vectors and vaccines as well as provides research services, process development and cGMP manufacturing, with a leadership team that has over 20 years of industry experience and serves as the company's foundation to build a dominant CDMO in Maryland.